Combined Therapy with a CCR2/CCR5 Antagonist and FGF21 Analogue Synergizes in Ameliorating Steatohepatitis and Fibrosis
Open accessThe DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Abstract
(1) Background: With new potential drug targets emerging, combination therapies appear attractive to treat non-alcoholic steatohepatitis (NASH) and fibrosis. Chemokine receptor CCR2/5 antagonists can improve fibrosis by reducing monocyte infiltration and altering hepatic macrophage subsets. Fibroblast growth factor 21 (FGF21) may improve NASH by modulating lipid and glucose metabolism. We compared effects of single drug to combination treatment as therapeutic strategies against NASH. (2) Methods: We analyzed serum samples and liver biopsies from 85 nonalcoholic fatty liver disease (NAFLD) patients. A CCR2/5 inhibitor (BMS-687681-02-020) and a pegylated FGF21 agonist (BMS-986171) were tested in male C57BL/6J mice subjected to dietary models of NASH and fibrosis (choline-deficient, L-amino acid-defined, high-fat diet (CDAHFD) up to 12 weeks; short- (2w) or long-term (6w) treatment). (3) Results: In NAFLD patients, chemokine CCL2 and FGF21 serum levels correlated with inflammatory serum markers, only CCL2 was significantly associated with advanced liver fibrosis. In rodent NASH, CCR2/5 inhibition significantly reduced circulating Ly6C+ monocytes and hepatic monocyte-derived macrophages, alongside reduced hepatic inflammation and fibrosis. FGF21 agonism decreased body weight, liver triglycerides and histological NASH activity. Combination treatment reflected aspects of both compounds upon short- and long-term application, thereby amplifying beneficial effects on all aspects of steatohepatitis and fibrosis. (4) Conclusions: CCR2/5 inhibition blocks hepatic infiltration of inflammatory monocytes, FGF21 agonism improves obesity-related metabolic disorders. Combined therapy ameliorates steatohepatitis and fibrosis more potently than single drug treatment in rodent NASH, corroborating the therapeutic potential of combining these two approaches in NASH patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, clinical trials using combinations have been disappointing despite promising preclinical data in mouse models.125,157”
From An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH (2023) · cites this paper as [157]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791 · cited 2×
“Fibrosis was evaluated using the NASH Clinical Research Network fibrosis staging system [48].”
MethodEASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
(2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.11.004 · Cited by 4,836
Mechanisms of NAFLD development and therapeutic strategies
Friedman, S. L., Neuschwander-Tetri, B. A., Rinella, M., & Sanyal, A. J. (2018) · Nature Medicine · doi:10.1038/s41591-018-0104-9 · Cited by 4,354
2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2018
American Diabetes Association (2018) · Diabetes Care · doi:10.2337/dc18-s002 · Cited by 3,159
The Natural History of Nonalcoholic Fatty Liver Disease: A Population-Based Cohort Study
Adams, L. A., Lymp, J. F., St. Sauver, J., Sanderson, S. O., Lindor, K. D., Feldstein, A., & Angulo, P. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.04.014 · Cited by 2,890 · cited 1×
“Chronic inflammatory processes result in liver fibrosis and ultimately liver cirrhosis, which is associated with a risk for developing hepatocellular carcinoma (HCC) [3].”
BackgroundEvolution of inflammation in nonalcoholic fatty liver disease: The multiple parallel hits hypothesis
Tilg, H., & Moschen, A. R. (2010) · Hepatology · doi:10.1002/hep.24001 · Cited by 2,548
Ekstedt, M., Hagström, H., Nasr, P., Fredrikson, M., Stål, P., Kechagias, S., & Hultcrantz, R. (2015) · Hepatology · doi:10.1002/hep.27368 · Cited by 2,287
FGF-21 as a novel metabolic regulator
Kharitonenkov, A., Shiyanova, T. L., Koester, A., Ford, A. M., Micanovic, R., Galbreath, E. J., Sandusky, G. E., Hammond, L. J., Moyers, J. S., Owens, R. A., et al. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23606 · Cited by 2,125
Mechanisms and disease consequences of nonalcoholic fatty liver disease
Loomba, R., Friedman, S. L., & Shulman, G. I. (2021) · Cell · doi:10.1016/j.cell.2021.04.015 · Cited by 2,002
Estes, C., Anstee, Q. M., Arias-Loste, M. T., Bantel, H., Bellentani, S., Caballeria, J., Colombo, M., Craxi, A., Crespo, J., Day, C. P., et al. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.05.036 · Cited by 1,980
Self-citation
Research works printed but not linked: 2
- Abdelmalek M.F.A.S. Nakajima A. Neuschwander-Tetri B.A. Goodman Z.D. Lawitz E.J. Harrison S.A. Jacobson I.M. Imajo K. Gunn N. Halegoua-DeMarzio D. Efficacy and safety of pegbelfermin in patients with nonalcoholic steatohepatitis and compensated cirrhosis: Results from the phase 2b, randomized, double-blind, placebo-controlled FALCON 2 study Proceedings of the American Association for the Study of Liver Diseases, The Liver Meeting, Virtual Conference 12–15 November 2021
- Sanyal A.J.A.N. Neuschwander-Tetri B.A. Goodman Z. Harrison S.A. Lawitz E.J. Gunn N. Imajo K. Ravendhran N. Akahane T. Boone B. Efficacy and safety of pegbelfermin in patients with nonalcoholic steatohepatitis and stage 3 fibrosis: Results from the phase 2b, randomized, double-blind, placebo-controlled FALCON 1 study Proceedings of the American Association for the Study of Liver Diseases, The Liver Meeting, Virtual Conference 12–15 November 2021
Cited by
Hepatic inflammatory responses in liver fibrosis
Hammerich, L., & Tacke, F. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00807-x · Cited by 803
“…mechanisms in liver fibrosis will (partly) depend on simultaneously ameliorating the underlying disease driver 227 , as suggested from animal models in which anti-inflammatory interventions in fibrotic NAFLD models were more effective in combination with metabolism-modifying drugs 228 .”
Self-citationAn integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH
Tacke, F., Puengel, T., Loomba, R., & Friedman, S. L. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.03.038 · Cited by 321
Self-citationAnstee, Q. M., Neuschwander-Tetri, B. A., Wai-Sun Wong, V., Abdelmalek, M. F., Rodriguez-Araujo, G., Landgren, H., Park, G. S., Bedossa, P., Alkhouri, N., Tacke, F., et al. (2024) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2023.04.003 · Cited by 179
Self-citationTreatment of liver fibrosis: Past, current, and future
Zhang, C.-Y., Liu, S., & Yang, M. J. (2023) · World Journal of Hepatology · doi:10.4254/wjh.v15.i6.755 · Cited by 109
Steatotic Liver Disease: Pathophysiology and Emerging Pharmacotherapies
Kokkorakis, M., Muzurović, E., Volčanšek, Š., Chakhtoura, M., Hill, M. A., Mikhailidis, D. P., & Mantzoros, C. S. (2024) · Pharmacological Reviews · doi:10.1124/pharmrev.123.001087 · Cited by 76
Current status and future perspectives of FGF21 analogues in clinical trials
Chui, Z. S. W., Shen, Q., & Xu, A. (2024) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2024.02.001 · Cited by 73
Guo, S., Zhang, Q., Guo, Y., Yin, X., Zhang, P., Mao, T., Tian, Z., & Li, X. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1497026 · Cited by 96
Wu, Y., Yan, Q., Yue, S.-Q., Pan, L., Yang, D., Tao, L.-S., Wei, Z., Fan, R., Qian, C., Han, M.-Q., et al. (2024) · International Journal of Biological Sciences · doi:10.7150/ijbs.92337 · Cited by 52
“Puengel T et al. found that combined treatment with CCR2/CCR5 antagonists and FGF21 analogs synergistically improved steatohepatitis and fibrosis [48].”
BackgroundFibroblast Growth Factor-21 as a Potential Therapeutic Target of Nonalcoholic Fatty Liver Disease
Raptis, D. D., Mantzoros, C. S., & Pοlyzos, S. A. (2023) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s352008 · Cited by 47
“Along these lines, in a recent meta-analysis of diagnostic accuracy studies, FGF-21 concentrations alone showed moderate sensitivity and specificity (0.62 and 0.78, respectively) for diagnosing NASH.93 However, both sensitivity and specificity increased (0.92 and 0.85, respectively), when FGF-21 concentrations were co…”
ResultInfluentialA roadmap for clinical trials in MASH-related compensated cirrhosis
Pericàs, J. M., Anstee, Q. M., Augustín, S., Bataller, R. A., Berzigotti, A., Ciudin, A., Francque, S., Abraldeṣ, J. G., Hernández–Gea, V., Pons, M., et al. (2024) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-024-00955-8 · Cited by 41
Self-citationPant, A., Bergsneider, B. H.-L., Srivastava, S., Kim, T., Jain, A., Bom, S., Shah, P. P., Kannapadi, N. V., Patel, K. K., Choi, J. H., et al. (2024) · OncoImmunology · doi:10.1080/2162402x.2024.2338965 · Cited by 35
Endotheliopathy in the metabolic syndrome: Mechanisms and clinical implications
Furuta, K., Tang, X., Islam, S., Tapia, A., Chen, Z. B., & Ibrahim, S. H. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108372 · Cited by 38
Therapeutic modulation of the liver immune microenvironment
Tilg, H., Adolph, T. E., & Tacke, F. (2023) · Hepatology · doi:10.1097/hep.0000000000000386 · Cited by 31
“Possibly, targeting immune cell recruitment would need to be embedded in a combinatorial treatment strategy, in which other compounds simultaneously target metabolic and/or inflammatory abnormalities.[196] Although chemokine-targeting approaches aim at reducing (inflammatory) immune cells in the liver, cellbased thera…”
BackgroundSelf-citationLin, Y., Liu, S., Sun, Y., Chen, C., Yang, S., Pei, G., Lin, M., Yu, J., Liu, X., Wang, H., et al. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102286 · Cited by 33
Puengel, T., & Tacke, F. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2374463 · Cited by 34
“However, first results of clinical trials using such combinations are now available and have so far been disappointing despite promising basic science data [104].”
Self-citationMechanism-guided drug development and treatment for liver fibrosis: a clinical perspective
Zeng, X., Huang, D., Zhu, Z., Cai, Q., Yang, Y., Lu, H., & Chen, J. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1574385 · Cited by 37
Marqués, P., Francisco, V., Martínez‐Arenas, L., Carvalho‐Gomes, Â., Domingo, E., Piqueras, L., Berenguer, M., & Sanz, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032313 · Cited by 33
“found positive correlations between circulating levels of this chemokine and serum levels of gamma-glutamyl transferase and fibroblast growth factor 21, as well as FIB-4 score (Table 1), suggesting a link between MCP-1/CCL2 and both liver damage and fibrosis [133].”
BackgroundResultInfluentialLiu, Y., Hao, Y., Boeckmans, J., Rodrigues, R. M., & He, Y. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108353 · Cited by 31
Vachliotis, I. D., & Pοlyzos, S. A. (2025) · Current Obesity Reports · doi:10.1007/s13679-025-00657-5 · Cited by 33
“However, the overall expression of MCP-1 and its receptor CCR2 seems to be increased in the liver of mice and patients with NAFLD [134 , 135 ], particularly in its advanced stages [136 , 137 ].”
Yuan, H., You, Y., He, Y., Wei, Y., Zhang, Y., Min, H., Li, C. R., & Chen, J. (2023) · Environmental Science & Technology · doi:10.1021/acs.est.3c03980 · Cited by 28
Kohlhepp, M. S., Liu, H., Tacke, F., & Guillot, A. (2023) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2023.1129831 · Cited by 27
Self-citationCurrent, emerging, and potential therapies for non-alcoholic steatohepatitis
Yang, Z. L., & Wang, L. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1152042 · Cited by 32
“pathogenesis and targets and different periods exhibits better efficacy (Rajamoorthi et al., 2017; Puengel et al., 2022).”
BackgroundZhang, N., Yao, H., Zhang, Z., Li, Z., Chen, X., Zhao, Y., Ju, R., He, J., Pan, H., Liu, X., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1131588 · Cited by 35
The role of macrophages in liver fibrosis: composition, heterogeneity, and therapeutic strategies
Ma, X., Qiu, J., Zou, S., Tan, L., & Miao, T. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1494250 · Cited by 35
Puengel, T., & Tacke, F. (2023) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2023.2230115 · Cited by 24
Self-citationEmerging therapeutic options for non-alcoholic fatty liver disease: A systematic review
Tidwell, J., Balassiano, N., Shaikh, A., & Nassar, M. (2023) · World Journal of Hepatology · doi:10.4254/wjh.v15.i8.1001 · Cited by 23
Innate immunity champions: The diverse functions of macrophages
Biscu, F., Zouzaf, A., Cicia, D., Pridans, C., & Matteoli, G. (2024) · European Journal of Immunology · doi:10.1002/eji.202451139 · Cited by 25
Boulos, M., Mousa, R. S., Jeries, N., Simaan, E., Alam, K., Bulus, B., & Assy, N. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26073448 · Cited by 26
Tada, Y., Kasai, K., Makiuchi, N., Igarashi, N., Kani, K., Takano, S., Honda, H., Yanagibashi, T., Watanabe, Y., Usui‐Kawanishi, F., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232113251 · Cited by 24
“The administration of a combination of a CCR2/ C-C chemokine receptor type 5 (CCR5) inhibitor and a fibroblast growth factor 21 analogue reduces the recruitment of these macrophages and liver fibrosis in a murine model of NASH [22].”
BackgroundYan, Y., Yuan, H., Yang, F., Na, H., Yu, X., Liu, J. R., & Wang, Y. (2024) · AMB Express · doi:10.1186/s13568-024-01756-7 · Cited by 18
Zhao, M., Yu, S., Zhang, M., Huang, Y., Dou, Z., Tian, B., Yang, L., & Lu, J. (2026) · Journal of Innate Immunity · doi:10.1159/000550397 · Cited by 18
“This strategy has shown potential in reducing liver fibrosis in studies on non-alcoholic fatty liver disease [123, 124].”
Decoding the CHI3L1/IL-13Rα2 signaling nexus in MASH-fibrosis pathogenesis
Zheng, Q., Cao, Y., Jiang, X., Wang, X., Wang, X., He, Y., Ma, W., Wu, H., Jiang, Y., WANG, T., et al. (2025) · Science Advances · doi:10.1126/sciadv.adz3223 · Cited by 14
“Chemokine receptor antagonists (e.g., CCR2/CCR5 inhibitors) reduce monocyte/macrophage infiltration ( 42 ), while apoptosis signal-regulating kinase 1 (ASK1) inhibitors mitigate oxidative stress and inflammation ( 43 ).”
The pivotal role of cytokines in liver disease pathogenesis and therapeutic potential
Li, L., Li, X., & Zhang, F. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1694582 · Cited by 15
Myeloid cell path to malignancy: insights into liver cancer
Ramirez, C. F. A., & Akkari, L. (2025) · Trends in cancer · doi:10.1016/j.trecan.2025.02.006 · Cited by 12
Ferrari-Cestari, M., Okano, S., Patel, P. J., Horsfall, L. U., Keshvari, S., Hume, D. A., Williams, S., Russell, A. W., Powell, E. E., & Irvine, K. M. (2022) · Digestive Diseases · doi:10.1159/000527784 · Cited by 9
Plasma Cytokeratin-18 Fragment Level Reflects the Metabolic Phenotype in Obesity
Góralska, J., Raźny, U., Gruca, A., Zdzienicka, A., Micek, A., Dembinska-Kiec, A., Solnica, B., & Malczewska-Malec, M. (2023) · Biomolecules · doi:10.3390/biom13040675 · Cited by 12
“revealed that combined therapy with a CCR2/CCR5 antagonist, which blocks the receptor for MCP-1, and an FGF-21 analogue synergizes in ameliorating steatohepatitis and fibrosis in mice subjected to dietary models of NASH and fibrosis [63].”
BackgroundResultExperimental model and novel therapeutic targets for non-alcoholic fatty liver disease development
Jin, Y., & Heo, K. (2023) · Korean Journal of Physiology and Pharmacology · doi:10.4196/kjpp.2023.27.4.299 · Cited by 11
“Furthermore, in clinical trials, CCR2/5 inhibitors have shown promise in improving liver fibrosis and inflammation in patients with NASH [95].”
BackgroundRomereim, S. M., Smykowski, M. R., Ball, E. K., Carey, E. G., Cuadra, M., Williams, A., Hickson, K., Haim, K., Sumith, M., Yu, Z., et al. (2025) · The American Journal of Sports Medicine · doi:10.1177/03635465241305411 · Cited by 7
“19 These represent an interesting ave-nue for preclinical investigation of agents that might prevent or minimize the severity of arthrofibrosis.”
FGF21-dependent alleviation of cholestasis-induced liver fibrosis by sodium butyrate
Yang, J., Chen, L., Zhao, S.-S., Du, C., Fan, Y.-Z., Liu, H., Li, Y., & Li, Y.-Z. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1422770 · Cited by 8
Fatty liver disease: time to target CCR5?
Brata, V. D., & Tacke, F. (2024) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2024.2366880 · Cited by 6
“As such, combining a fibroblast growth factor 21 (FGF-21) analogue with a CCR2/CCR5 inhibitor synergized in ameliorating steatohepatitis and fibrosis in dietary mouse models of MASH [22].”
BackgroundSelf-citationWang, X., Wei, Z., Xiang, Q., Tang, L., & Xie, W. (2025) · Microorganisms · doi:10.3390/microorganisms13081894 · Cited by 6
“Concurrently, FGF21 agonism resulted in reduced body weight, liver triglycerides, and histological MASH activity [123].”
Bone marrow monocytes sustain NK cell-poiesis during non-alcoholic steatohepatitis
Bourayou, E., Perchet, T., Meunier, S., Bouvier, H., Mailhé, M.-P., Melanitou, E., Cumano, A., & Golub, R. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.113676 · Cited by 9
Chen, Y., Jia, B., Tong, X., Yin, S., Ni, W., Zhao, Q., Shi, J., & Li, J. (2025) · Hepatology Communications · doi:10.1097/hc9.0000000000000864 · Cited by 6
“[81] However, clinical evidence regarding the synergistic effects of combination therapy with CCR2/5 inhibitors is limited.”
Self-citationHu, K., Liu, S., Sheng, S., Zhang, S., Li, B., Sun, B., & Xia, A. (2026) · iLiver · doi:10.1016/j.iliver.2026.100234 · Cited by 6
Kishinaka, S., Kawashita, E., Nishizaki, T., Ishihara, K., & Akiba, S. (2024) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b24-00035 · Cited by 4
Hussain, Z. (2025) · Exploration of Digestive Diseases · doi:10.37349/edd.2025.100563 · Cited by 3
Preclinical Models and Promising Pharmacotherapeutic Strategies in Liver Fibrosis: An Update
Kolarić, T. O., Kuna, L., Čović, M., Roguljić, H., Matić, A., Sikora, R., Hefer, M., Petrovic, A. G., Mihaljević, V., Smolić, R., et al. (2023) · Current Issues in Molecular Biology · doi:10.3390/cimb45050270 · Cited by 3
Zhang, C., Sui, Y., Liu, S., & Yang, M. J. (2023) · Exploration of Digestive Diseases · doi:10.37349/edd.2023.00029 · Cited by 4
Kamiya, A., & Ida, K. (2022) · Cells · doi:10.3390/cells11233751 · Cited by 3
“The suppression of inflammation is one of the targets of NASH therapy; the chemokine receptor antagonist was considered to be a candidate for NASH treatments [26].”
BackgroundWang, J., Zeng, X., Xue, W., Jia, Q., Jiang, Q., Huo, C., Jiao, X., Zhang, J., Wang, Y., Tian, L., et al. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.113273 · Cited by 2
Scharpf, B. R., Ruetten, H. M., Sandhu, J., Wegner, K. A., Chandrashekar, S., Fox, O., Turco, A. E., Cole, C., Arendt, L. M., Strand, D. W., et al. (2025) · Disease Models & Mechanisms · doi:10.1242/dmm.052012 · Cited by 4
“Additionally, CCR2 antagonists could prove to be even more potent when used in combination with other drugs, like an FGF21 analog, which further reduces fibrosis in rodents (Puengel et al., 2022).”
Yin, M., Zhang, Y., Liu, S., & Li, X. (2026) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-026-00921-z · Cited by 2
“Similarly, pairing chemokine antagonists with metabolic modulators, such as FGF21 agonists [141] or GLP-1R agonists [142], offers a rational path to simultaneously target inflammatory infiltration, fibrogenic signaling, and core metabolic disturbances.”
Role of Kupffer cells and other immune cells
Puengel, T., & Tacke, F. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95262-0.00024-3
Self-citationLiver Steatosis: From Lipotoxicity to Cellular Damage
Puengel, T., & Tacke, F. (2024) · Springer eBooks · doi:10.1007/978-981-97-9519-2_4 · Cited by 3
Self-citationOzono, Y., Kawakami, H., Hatada, H., Uchiyama, N., Ogawa, S., Uchida, K., Tamura, H., Komaki, Y., Nakamura, K., Iwakiri, H., et al. (2026) · BMC Gastroenterology · doi:10.1186/s12876-026-04610-1
“This duration aligns with previous studies that established NASH models using CDAHFD [29, 30].”
Cutrone, A. M., Yeh, H., Uygun, K., & Usta, O. B. (2026) · Annual Review of Biomedical Engineering · doi:10.1146/annurev-bioeng-081325-053420
Cens, A., Staels, B., & Paumelle, R. (2026) · Revue Francophone des Laboratoires · doi:10.1016/s1773-035x(26)76566-7 · Cited by 1
Peptide hormone-based combinational pharmacotherapies for chronic metabolic diseases
Chui, Z. S. W., Xue, Y., Wu, X., & Xu, A. (2026) · Pharmacological Reviews · doi:10.1016/j.pharmr.2026.100150
Ye, Z., Liu, M., Wu, Q., Wang, J., & Lyu, W. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1896838 · Cited by 1
Metadata
- Authors
- Puengel, T., Lefere, S., Hundertmark, J., Kohlhepp, M., Penners, C., Van de Velde, F., Lapauw, B., Hoorens, A., Devisscher, L., Geerts, A., Boehm, S., Zhao, Q., Krupinski, J., Charles, E. D., Zinker, B., & Tacke, F.
- Affiliations
- Universitätsklinikum Aachen (DE)
- Ghent University (BE)
- Charité – Universitätsmedizin Berlin (DE)
- Department of Endocrinology, Ghent University, B-9000 Ghent, Belgium
- Ghent University Hospital (BE)
- Bristol-Myers Squibb (United States) (US)
- Corresponding author
- Puengel, Tobias
- Lefere, Sander
- ORCID
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2022-06-15
- Volume
- 23
- Issue
- 12
- Pages
- 6696
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC9224277
- OpenAlex
- W4282967424
- Cited by
- 59
- References
- 49
- Citations by year
- 2026: 8 · 2025: 12 · 2024: 17 · 2023: 19 · 2022: 3
- FWCI
- 9.20
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Ghent University Academic Bibliography (Ghent University) (publishedVersion, other-oa)
- RWTH Publications (RWTH Aachen)
- Funders
- German Research Foundation (403224013)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fibroblast Growth Factor Research
- Keywords
- nonalcoholic steatohepatitis, liver fibrosis, FGF21 analogues, combination therapy, monocyte infiltration, hepatic macrophages, liver inflammation, choline-deficient L-amino acid-defined diet, high-fat diet, non-alcoholic fatty liver disease
- MeSH terms
- Animals, Disease Models, Animal, Fibroblast Growth Factors, Fibrosis, Humans, Liver, Liver Cirrhosis, Male, Mice, Inbred C57BL, Receptors, CCR5, Mice, Receptors, CCR2, Diet, High-Fat, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.